Global Immuno-oncology Clinical Trials Market by Design (Expanded Access Trials, Interventional Trials, Observational Trials), Phase (Phase I, Phase II, Phase III), Indication - Forecast 2024-2030- Product Image

Sale

Global Immuno-oncology Clinical Trials Market by Design (Expanded Access Trials, Interventional Trials, Observational Trials), Phase (Phase I, Phase II, Phase III), Indication - Forecast 2024-2030

Report
197 Pages
March 2024
Region: Global
360iResearch™
ID: 5674772

UP TO €846EUR$875USD£717GBP OFF until Dec 31^st 2024

The Immuno-oncology Clinical Trials Market size was estimated at USD 6.13 billion in 2023, USD 6.58 billion in 2024, and is expected to grow at a CAGR of 11.17% to reach USD 12.87 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Immuno-oncology Clinical Trials Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Immuno-oncology Clinical Trials Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Immuno-oncology Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, BioNTech SE, Bristol Myers Squibb Company, Exscientia PLC, F. Hoffmann-La Roche Ltd., ICON PLC, IO Biotech ApS, IQVIA Inc., Laboratory Corporation of America Holdings, Medpace, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Rubius Therapeutics, Inc., and Syneos Health, Inc.

Market Segmentation & Coverage

This research report categorizes the Immuno-oncology Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

Design
- Expanded Access Trials
- Interventional Trials
- Observational Trials
Phase
- Phase I
- Phase II
- Phase III
- Phase IV
Indication
- Hematological Cancer
- Solid Tumors

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Immuno-oncology Clinical Trials Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Immuno-oncology Clinical Trials Market?
What are the technology trends and regulatory frameworks in the Immuno-oncology Clinical Trials Market?
What is the market share of the leading vendors in the Immuno-oncology Clinical Trials Market?
Which modes and strategic moves are suitable for entering the Immuno-oncology Clinical Trials Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Immuno-oncology Clinical Trials Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of cancer and the growing adoption of targeted therapy
5.1.1.2. Growing significance of companion diagnostics in drug development
5.1.1.3. Rapidly increasing demand for personalized medicine
5.1.2. Restraints
5.1.2.1. Requirement of high capital investments and low cost-benefit ratio
5.1.3. Opportunities
5.1.3.1. Advancements in immuno-oncology testing
5.1.3.2. Increasing financial support from the government for cancer R&D
5.1.4. Challenges
5.1.4.1. Huge complexity in the production and manufacturing processes
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Immuno-oncology Clinical Trials Market, by Design

6.1. Introduction
6.2. Expanded Access Trials
6.3. Interventional Trials
6.4. Observational Trials

7. Immuno-oncology Clinical Trials Market, by Phase

7.1. Introduction
7.2. Phase I
7.3. Phase II
7.4. Phase III
7.5. Phase IV

8. Immuno-oncology Clinical Trials Market, by Indication

8.1. Introduction
8.2. Hematological Cancer
8.3. Solid Tumors

9. Americas Immuno-oncology Clinical Trials Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Immuno-oncology Clinical Trials Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Immuno-oncology Clinical Trials Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. AstraZeneca PLC
13.1.2. BioNTech SE
13.1.3. Bristol Myers Squibb Company
13.1.4. Exscientia PLC
13.1.5. F. Hoffmann-La Roche Ltd.
13.1.6. ICON PLC
13.1.7. IO Biotech ApS
13.1.8. IQVIA Inc.
13.1.9. Laboratory Corporation of America Holdings
13.1.10. Medpace, Inc.
13.1.11. Merck KGaA
13.1.12. Novartis AG
13.1.13. Pfizer Inc.
13.1.14. Rubius Therapeutics, Inc.
13.1.15. Syneos Health, Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET RESEARCH PROCESS
FIGURE 2. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
FIGURE 3. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET DYNAMICS
FIGURE 7. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2030 (%)
FIGURE 8. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
FIGURE 10. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 12. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 6. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 10. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 15. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 27. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 28. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 29. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 30. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 31. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 32. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 44. CHINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 45. CHINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 46. CHINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. INDIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 48. INDIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 49. INDIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. JAPAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 54. JAPAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 55. JAPAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. THAILAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 72. THAILAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 73. THAILAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 82. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 83. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. EGYPT IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 85. EGYPT IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 86. EGYPT IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. FINLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 88. FINLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 89. FINLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 91. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 92. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 94. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 95. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 100. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 101. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. NORWAY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 109. NORWAY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 110. NORWAY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. POLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 112. POLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 113. POLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. QATAR IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 115. QATAR IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 116. QATAR IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 127. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 128. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. TURKEY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 136. TURKEY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 137. TURKEY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 145. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 146. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET LICENSE & PRICING

Companies Mentioned

AstraZeneca PLC
BioNTech SE
Bristol Myers Squibb Company
Exscientia PLC
F. Hoffmann-La Roche Ltd.
ICON PLC
IO Biotech ApS
IQVIA Inc.
Laboratory Corporation of America Holdings
Medpace, Inc.
Merck KGaA
Novartis AG
Pfizer Inc.
Rubius Therapeutics, Inc.
Syneos Health, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	197
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 6.58 Billion
Forecasted Market Value ( USD ) by 2030	$ 12.87 Billion
Compound Annual Growth Rate	11.1%
Regions Covered	Global
No. of Companies Mentioned	15

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3263EUR$3,374USD£2,763GBP €3625EUR$3,749USD£3,070GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4133EUR$4,274USD£3,500GBP €4593EUR$4,749USD£3,889GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5004EUR$5,174USD£4,238GBP €5560EUR$5,749USD£4,708GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5874EUR$6,074USD£4,975GBP €6527EUR$6,749USD£5,527GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7615EUR$7,874USD£6,449GBP €8461EUR$8,749USD£7,165GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Immuno-Oncology Clinical Trials Market Report 2023-2033

Global Immuno Oncology Assays Market by Indication (Bladder Cancer, Colorectal Cancer, Lung Cancer), Product (Consumables, Software), Technology, Application - Forecast 2024-2030

Immuno-Oncology - Thematic Intelligence

Immuno-Oncology Drug Development: Analytical Tool

Global Immuno-Oncology Market by Type (Cancer Vaccines, Checkpoint Inhibitors, Cytokines), Indication (Breast Cancer, Colorectal Cancer, Lung Cancer), End-Users - Forecast 2024-2030

About the Immuno Oncology Clinical Trials Market